Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 257

1.

Raising the bar for antineoplastic agents: how to choose threshold values for superiority trials in advanced solid tumors.

Sobrero AF, Pastorino A, Sargent DJ, Bruzzi P.

Clin Cancer Res. 2014 Sep 17. pii: clincanres.1505.2014. [Epub ahead of print]

PMID:
25231398
[PubMed - as supplied by publisher]
2.

Looking forward to genetically edited fruit crops.

Nagamangala Kanchiswamy C, Sargent DJ, Velasco R, Maffei ME, Malnoy M.

Trends Biotechnol. 2014 Aug 12. pii: S0167-7799(14)00147-4. doi: 10.1016/j.tibtech.2014.07.003. [Epub ahead of print]

PMID:
25129425
[PubMed - as supplied by publisher]
3.

Design of Phase I Combination Trials: Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee.

Paller CJ, Bradbury PA, Ivy SP, Seymour L, LoRusso PM, Baker L, Rubinstein L, Huang E, Collyar D, Groshen S, Reeves S, Ellis LM, Sargent DJ, Rosner GL, LeBlanc ML, Ratain MJ.

Clin Cancer Res. 2014 Aug 15;20(16):4210-4217. Review.

PMID:
25125258
[PubMed - as supplied by publisher]
4.

Center-Within-Trial Versus Trial-Level Evaluation of Surrogate Endpoints.

Renfro LA, Shi Q, Xue Y, Li J, Shang H, Sargent DJ.

Comput Stat Data Anal. 2014 Oct 1;78:1-20.

PMID:
25061255
[PubMed]
5.

Evaluation of a chemoresponse assay as a predictive marker in the treatment of recurrent ovarian cancer: further analysis of a prospective study.

Tian C, Sargent DJ, Krivak TC, Powell MA, Gabrin MJ, Brower SL, Coleman RL.

Br J Cancer. 2014 Aug 26;111(5):843-50. doi: 10.1038/bjc.2014.375. Epub 2014 Jul 8.

PMID:
25003664
[PubMed - in process]
Free PMC Article
6.

Association of Age With Survival in Patients With Metastatic Colorectal Cancer: Analysis From the ARCAD Clinical Trials Program.

Lieu CH, Renfro LA, de Gramont A, Meyers JP, Maughan TS, Seymour MT, Saltz L, Goldberg RM, Sargent DJ, Eckhardt SG, Eng C.

J Clin Oncol. 2014 Jul 7. pii: JCO.2013.54.9329. [Epub ahead of print]

PMID:
25002720
[PubMed - as supplied by publisher]
7.

Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147.

Gonsalves WI, Mahoney MR, Sargent DJ, Nelson GD, Alberts SR, Sinicrope FA, Goldberg RM, Limburg PJ, Thibodeau SN, Grothey A, Hubbard JM, Chan E, Nair S, Berenberg JL, McWilliams RR; Alliance for Clinical Trials in Oncology.

J Natl Cancer Inst. 2014 Jun 12;106(7). pii: dju106. doi: 10.1093/jnci/dju106. Print 2014 Jul. Erratum in: J Natl Cancer Inst. 2014 Jul;106(7). doi:10.1093/jnci/dju228.

PMID:
24925349
[PubMed - indexed for MEDLINE]
8.

Molecular testing for lymph node metastases as a determinant of colon cancer recurrence: results from a retrospective multicenter study.

Sargent DJ, Shi Q, Gill S, Louvet C, Everson RB, Kellner U, Clancy TE, Pipas JM, Resnick MB, Meyers MO, Wu TT, Huntsman D, Validire P, Farooq U, Pavey ES, Beaudry G, Haince JF, Fradet Y.

Clin Cancer Res. 2014 Aug 15;20(16):4361-9. doi: 10.1158/1078-0432.CCR-13-2659. Epub 2014 Jun 11.

PMID:
24919572
[PubMed - in process]
9.

Impact of copula directional specification on multi-trial evaluation of surrogate endpoints.

Renfro LA, Shang H, Sargent DJ.

J Biopharm Stat. 2014 Jun 6. [Epub ahead of print]

PMID:
24905465
[PubMed - as supplied by publisher]
10.

Exploring the statistical and clinical impact of two interim analyses on the Phase II design with option for direct assignment.

An MW, Mandrekar SJ, Edelman MJ, Sargent DJ.

Contemp Clin Trials. 2014 Jul;38(2):157-62. doi: 10.1016/j.cct.2014.04.007. Epub 2014 Apr 24.

PMID:
24768938
[PubMed - in process]
11.

Germline variation in colorectal risk Loci does not influence treatment effect or survival in metastatic colorectal cancer.

Sanoff HK, Renfro LA, Poonnen P, Ambadwar P, Sargent DJ, Goldberg RM, McLeod H.

PLoS One. 2014 Apr 11;9(4):e94727. doi: 10.1371/journal.pone.0094727. eCollection 2014.

PMID:
24727911
[PubMed - in process]
Free PMC Article
12.

Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial).

Sha D, Lee AM, Shi Q, Alberts SR, Sargent DJ, Sinicrope FA, Diasio RB.

Clin Cancer Res. 2014 Jun 15;20(12):3319-27. doi: 10.1158/1078-0432.CCR-14-0069. Epub 2014 Apr 11.

PMID:
24727325
[PubMed - in process]
13.

Randomized phase II clinical trials.

Jung SH, Sargent DJ.

J Biopharm Stat. 2014;24(4):802-16. doi: 10.1080/10543406.2014.901343.

PMID:
24697589
[PubMed - in process]
Free PMC Article
14.

KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).

Yoon HH, Tougeron D, Shi Q, Alberts SR, Mahoney MR, Nelson GD, Nair SG, Thibodeau SN, Goldberg RM, Sargent DJ, Sinicrope FA; Alliance for Clinical Trials in Oncology.

Clin Cancer Res. 2014 Jun 1;20(11):3033-43. doi: 10.1158/1078-0432.CCR-13-3140. Epub 2014 Mar 31.

PMID:
24687927
[PubMed - in process]
15.

Evaluation of alternate categorical tumor metrics and cut points for response categorization using the RECIST 1.1 data warehouse.

Mandrekar SJ, An MW, Meyers J, Grothey A, Bogaerts J, Sargent DJ.

J Clin Oncol. 2014 Mar 10;32(8):841-50. doi: 10.1200/JCO.2013.52.3019. Epub 2014 Feb 10.

PMID:
24516033
[PubMed - indexed for MEDLINE]
16.

Comparison of FOLFIRI with or without cetuximab in patients with resected stage iii colon cancer; NCCTG (Alliance) intergroup trial N0147.

Huang J, Nair SG, Mahoney MR, Nelson GD, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Quesenberry JT, Thibodeau SN, Smyrk TC, Grothey A, Sinicrope FA, Webb TA, Farr GH Jr, Pockaj BA, Berenberg JL, Mooney M, Sargent DJ, Alberts SR; Alliance for Clinical Trials in Oncology.

Clin Colorectal Cancer. 2014 Jun;13(2):100-9. doi: 10.1016/j.clcc.2013.12.002. Epub 2013 Dec 28.

PMID:
24512953
[PubMed - in process]
17.

Multi-state models for colon cancer recurrence and death with a cured fraction.

Conlon AS, Taylor JM, Sargent DJ.

Stat Med. 2014 May 10;33(10):1750-66. doi: 10.1002/sim.6056. Epub 2013 Dec 5.

PMID:
24307330
[PubMed - in process]
18.

Calibration of quality-adjusted life years for oncology clinical trials.

Sloan JA, Sargent DJ, Novotny PJ, Decker PA, Marks RS, Nelson H.

J Pain Symptom Manage. 2014 Jun;47(6):1091-1099.e3. doi: 10.1016/j.jpainsymman.2013.07.016. Epub 2013 Nov 15.

PMID:
24246787
[PubMed - in process]
19.

Application of tumor measurement-based metrics in the real world.

An MW, Mandrekar SJ, Sargent DJ.

J Clin Oncol. 2013 Dec 1;31(34):4374. doi: 10.1200/JCO.2013.52.3662. Epub 2013 Oct 28. No abstract available.

PMID:
24166528
[PubMed - indexed for MEDLINE]
20.

Expression of Fragaria vesca PIP aquaporins in response to drought stress: PIP down-regulation correlates with the decline in substrate moisture content.

Ĺ urbanovski N, Sargent DJ, Else MA, Simpson DW, Zhang H, Grant OM.

PLoS One. 2013 Sep 23;8(9):e74945. doi: 10.1371/journal.pone.0074945. eCollection 2013.

PMID:
24086403
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk